Floatz logo

Cediranib

Metastatic Malignant Neoplasm in the Brain

M.D. Anderson Cancer CenterSmall moleculePhase 2Active
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

17 Active assets in the Metastatic Malignant Neoplasm in the Brain cohort.

Asset / SponsorPhaseRating
Copper Cu 64-DOTA-Trastuzumab
City of Hope Medical Center
Phase 4BB
FULVESTRANT
Nationwide Children's Hospital
Phase 2BB
Namenda
NRG Oncology
Phase 3BB
Memantine Hydrochloride
NRG Oncology
Phase 3B
Atezolizumab
National Cancer Institute (NCI)
Phase 2B

View all 30 →

Same molecule, other indications

Cediranib is also rated in:

gliosarcomaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent NeuroblastomaDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Colon CancerDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →